5/29
08:34 am
vtgn
Vistagen to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
Vistagen to Present at the Jefferies Global Healthcare Conference [Yahoo! Finance]
5/29
08:30 am
vtgn
Vistagen to Present at the Jefferies Global Healthcare Conference
Low
Report
Vistagen to Present at the Jefferies Global Healthcare Conference
5/23
08:40 am
vtgn
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference [Yahoo! Finance]
Medium
Report
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference [Yahoo! Finance]
5/23
08:30 am
vtgn
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Medium
Report
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
5/7
08:49 am
vtgn
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]
Low
Report
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]
5/7
08:30 am
vtgn
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Low
Report
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
4/25
08:30 am
vtgn
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Low
Report
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
4/24
10:47 am
vtgn
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression [Seeking Alpha]
Low
Report
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression [Seeking Alpha]
4/9
08:30 am
vtgn
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Medium
Report
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
4/1
08:30 am
vtgn
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Medium
Report
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
3/20
09:04 pm
vtgn
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish [Seeking Alpha]
Low
Report
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish [Seeking Alpha]
3/17
03:16 am
vtgn
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]
Low
Report
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]
3/11
08:30 am
vtgn
Vistagen to Present at Stifel 2024 Virtual CNS Days
Low
Report
Vistagen to Present at Stifel 2024 Virtual CNS Days